Clinical Trial

Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Elderly AML patients receiving conventional chemotherapy have poor prognosis. Allo-HSCT offers better long-term survival than chemotherapy, while high TRM limits its use. Current research focuses more on improving conditioning regimens to reduce TRM. Studies suggest Bu/Flu/Cy/ATG are safer and more effective for elderly AML haplo-HSCT, lowering TRM. However, prospective randomized trials are lacking. This study aims to compare Bu/Flu/Cy/ATG vs. Bu/Cy/ATG to determine if TRM can be reduced in elderly AML undergoing haplo-HSCT.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-19.
Trial Details
NCT Number NCT06946602
Lead Sponsor Peking University People's Hospital
Conditions AML, Elderly
Enrollment 307 participants
Start Date 2025-05-20
Primary Completion 2027-10-31 (estimated)
Study Completion 2027-10-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-11